Edition:

U.S.

Africa

Arabic

Argentina

Brazil

Canada

China

France

Germany

India

Italy

Japan

Latin America

Mexico

Russia

Spain

United Kingdom

Home

Business

Business Home

Economy

Technology

Media

Small
Business

Legal

Deals

Earnings

Social Pulse

Business Video

The Freeland File

Aerospace & Defense

Markets

Markets
Home

U.S.
Markets

European Markets

Asian
Markets

Global Market Data

Indices

M&A

Stocks

Bonds

Currencies

Commodities

Futures

Funds

peHUB

World

World Home

U.S.

Brazil

China

Euro
Zone

Japan

Mexico

Russia

India Insight

World Video

Reuters Investigates

Decoder

Politics

Politics Home

Election 2012

Campaign Polling

Tales from the
Trail

Political Punchlines

Supreme Court

Politics Video

Tech

Technology
Home

MediaFile

Science

Tech Video

Tech Tonic

Social Pulse

Opinion

Opinion Home

Chrystia Freeland

John Lloyd

Felix
Salmon

Jack
Shafer

David
Rohde

Bernd
Debusmann

Nader
Mousavizadeh

Lucy P.
Marcus

David
Cay Johnston

Bethany
McLean

Anatole Kaletsky

Edward
Hadas

Hugo
Dixon

Ian
Bremmer

Lawrence
Summers

Susan
Glasser

The Great
Debate

Steven Brill

Jack
& Suzy Welch

Frederick Kempe

Christopher Papagianis

Mark Leonard

Breakingviews

Equities

Credit

Private Equity

M&A

Macro & Markets

Politics

Breakingviews Video

Money

Money Home

Tax Break

Lipper Awards 2012

Global
Investing

MuniLand

Unstructured Finance

Linda
Stern

Mark
Miller

John
Wasik

James Saft

Analyst Research

Alerts

Watchlist

Portfolio

Stock Screener

Fund Screener

Personal Finance Video

Money Clip

Investing 201

Life

Health

Sports

Olympics

Arts

Faithworld

Business Traveler

Entertainment

Oddly
Enough

Lifestyle Video

Pictures

Pictures
Home

Reuters
Photographers

Full Focus

Video

Reuters TV

Reuters News

Article

Comments (0)

Pictures

Ancient
finds

A look at the items discovered during archaeological digs.  Slideshow

Follow Reuters

Facebook

Twitter

RSS

YouTube

Read

Obama
heading to Colorado to meet families of shooting victims |

6:19am EDT

Mexico
urges U.S. to review gun laws after Colorado shooting

21 Jul 2012

Damascus
chaos strikes fear in Assad's Alawite bastion

21 Jul 2012

U.S.
F-16 fighter crashes off coast of Japan

2:38am EDT

Colorado
Shooting: Civil Lawsuits Likely

20 Jul 2012

Discussed

136
Fourteen killed in
Denver movie theater shooting

133
Obama allies tell
Romney to ”quit whining” about Bain attacks

117
Syrian battles
rage in capital, Russia pressed

Watched

Latest
solar flare dazzling but not dangerous Fri, Jul 20
2012

Deliveries
and deliberations in Colorado shooting Sat, Jul 21
2012

'Emotional'
android shows new face of robotics Wed, Jul 18
2012

Pictures

Reuters
Photojournalism

Our day's top images, in-depth photo essays and offbeat slices of life. See
the best of Reuters photography.  See more

Tragedy
in Denver

A gunman opens fire at a midnight screening of the Dark Knight.  Slideshow

Hunger
in Yemen

Aid agencies estimate half the country is now malnourished.  Slideshow

HIV drug creator Antonin Holy dies at 75

Tweet

Share
this

Email

Print

Related News

Gilead
wins first approval of drug to prevent HIV

Mon, Jul 16 2012

Scientists
see AIDS vaccine within reach after decades

Sun, Jul 15 2012

GSK's
HIV drug beats Gilead market leader in study

Wed, Jul 11 2012

FDA
approves first at-home HIV test from OraSure

Tue, Jul 3 2012

FDA
advisers back Onyx blood cancer drug

Wed, Jun 20 2012

Related Topics

Science »

PRAGUE | Tue Jul 17, 2012
8:18am EDT

PRAGUE (Reuters) - Czech scientist Antonin
Holy, who played an important role in creating drugs to treat HIV and AIDS, has
died at the age of 75, the Czech Academy of Sciences said on
Tuesday.

Holy died on Monday - the day U.S. health regulators for the first time
approved using Truvada, a drug that he helped develop, to prevent infection in
people who face a high risk of contracting the virus that causes AIDS.
[ID:nL2E8IG8TG]

Truvada includes Viread, a drug used to treat HIV, which Holy created with
virologist Erik De Clercq.

Holy, who won a number of prestigious awards including the European Union's
Descartes Prize for science in 2001, also helped develop the drug Vestide, used
for the treatment of retinitis in AIDS patients, and Hepsera to treat hepatitis
B. He died after battling an unspecified long-term disease.

"It is a huge loss," said Zdenek Havlas, a former chief of the Institute of
Organic Chemistry and Biochemistry at the Czech Academy of Sciences, who worked
there with Holy for 35 years. "He belonged and he always will belong among the
greatest chemists and scientists."

"He had a special talent for looking at a chemical structure to tell
immediately whether it was worth continuing to explore and whether it would have
any effects."

Under communist rule in the former Czechoslovakia, Holy was banned from
supervising students and worked alone with the help of just one
technician.

After the fall of the communist regime in 1989, he was allowed to build his
team and began to give lectures at Czech universities. In 2008 he received an
honorary professorship at the University of Manchester's School of Chemistry in
Britain.

U.S. pharmaceutical company Gilead Sciences Inc, the makers of Truvada,
donated millions of dollars to the Institute of Organic Chemistry and
Biochemistry, and part of that donation was used to fund his research.

(Reporting by Jana Mlcochova; Editing by Chris
Wickham and Pravin Char)

Science

Related Quotes and News

Company

Price

Related News

Tweet this

Link
this

Share
this

Digg
this

Email

Reprints

We welcome comments that advance the story through
relevant opinion, anecdotes, links and data. If you see a comment that you
believe is irrelevant or inappropriate, you can flag it to our editors by using
the report abuse links. Views expressed in the comments do not represent those
of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/

Comments (0)

Be the first to comment on reuters.com.

Add yours using the box above.

Edition:

U.S.

Africa

Arabic

Argentina

Brazil

Canada

China

France

Germany

India

Italy

Japan

Latin America

Mexico

Russia

Spain

United Kingdom

Back to top

Reuters.com

Business

Markets

World

Politics

Technology

Opinion

Money

Pictures

Videos

Site
Index

Legal

Bankruptcy Law

California Legal

New
York Legal

Securities Law

Support &
Contact

Support

Corrections

Connect with
Reuters

Twitter

Facebook

LinkedIn

RSS

Podcast

Newsletters

Mobile

About

Privacy
Policy

Terms of
Use

AdChoices

Copyright

Our Flagship financial information platform incorporating
Reuters Insider

An ultra-low latency infrastructure for electronic trading
and data distribution

A connected approach to governance, risk and
compliance

Our next generation legal research platform

Our global tax workstation

Thomsonreuters.com

About Thomson
Reuters

Investor
Relations

Careers

Contact Us

Thomson Reuters is the world's
largest international multimedia news agency, providing investing news, world news, business news, technology news, headline
news, small business
news, news alerts, personal finance, stock market, and mutual funds information
available on Reuters.com, video,
mobile, and interactive
television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair
presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at
least 15 minutes. For a complete list of exchanges
and delays, please click here.